Topics

FDA Accepting Less Data, More Surrogate Endpoints in Trials

10:26 EST 15 Jan 2020 | Medscape

Less stringent clinical trial requirements and expedited pathways have come with positive and negative results, an editorialist writes. He suggests ways to reform the reform.
Medscape Medical News

Original Article: FDA Accepting Less Data, More Surrogate Endpoints in Trials

NEXT ARTICLE

More From BioPortfolio on "FDA Accepting Less Data, More Surrogate Endpoints in Trials"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...